ELI LILLY & Co
LLYAPI behind this page
LLY FY 2025 request
Playground key active
/api/financials?ticker=LLY&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Revenue | 65,179 | 45,043 | +44.7% |
Show Product Lines breakouts |
|||
| Cardiometabolic Health · Non Us | 14,357 | 7,671 | +87.2% |
| Cardiometabolic Health · US | 33,864 | 21,850 | +55.0% |
| Collaboration and Other Revenue [Member] | 4,221 | 4,295 | -1.7% |
| Immunology · Non Us | 2,283 | 1,935 | +18.0% |
| Immunology · US | 2,964 | 2,458 | +20.6% |
| Jardiance | 3,432 | 3,341 | +2.7% |
| Jardiance · Milestone Payments, Sales-based | 200 | — | — |
| Jardiance · Non Us | 1,849 | 1,743 | +6.1% |
| Jardiance · One Time Payment Received | 370 | 300 | +23.3% |
| Jardiance · US | 1,582 | 1,598 | -1.0% |
| Mounjaro · Non Us | 9,315 | 2,590 | +259.7% |
| Mounjaro · US | 13,651 | 8,950 | +52.5% |
| Neuroscience · Non Us | 394 | 694 | -43.2% |
| Neuroscience · US | 997 | 780 | +27.8% |
| Oncology · Non Us | 4,024 | 3,717 | +8.3% |
| Oncology · US | 5,352 | 5,036 | +6.3% |
| Other cardiometabolic health · Non Us | 1,773 | 1,778 | -0.3% |
| Other cardiometabolic health · US | 2,233 | 2,682 | -16.7% |
| Other immunology · Non Us | 1,053 | 827 | +27.3% |
| Other immunology · US | 631 | 306 | +106.2% |
| Other oncology · Non Us | 1,765 | 1,831 | -3.6% |
| Other oncology · US | 1,888 | 1,615 | +16.9% |
| Other · Non Us | 639 | 652 | -2.0% |
| Other · US | 304 | 251 | +21.1% |
| Product | 60,958 | 40,748 | +49.6% |
| Taltz · Non Us | 1,230 | 1,108 | +11.0% |
| Taltz · US | 2,333 | 2,152 | +8.4% |
| Trulicity · Non Us | 1,362 | 1,560 | -12.7% |
| Trulicity · US | 2,914 | 3,694 | -21.1% |
| Verzenio · Non Us | 2,259 | 1,886 | +19.8% |
| Verzenio · US | 3,464 | 3,421 | +1.3% |
| Zepbound · Non Us | 58 | — | — |
| Zepbound · US | 13,484 | 4,926 | +173.7% |
Show Business Segments breakouts |
|||
| Reportable Segment | 65,179 | 45,043 | +44.7% |
Show Geography breakouts |
|||
| CN | 1,951 | 1,660 | +17.5% |
| Europe | 11,558 | 6,921 | +67.0% |
| JP | 2,132 | 1,815 | +17.5% |
| Non Us | 21,698 | 14,668 | +47.9% |
| Rest of world | 6,057 | 4,271 | +41.8% |
| US | 43,481 | 30,375 | +43.1% |
| Cost of Revenue | 11,052 | 8,418 | +31.3% |
Show Business Segments breakouts |
|||
| Reportable Segment | 11,052 | 8,418 | +31.3% |
| Research And Development Expense Excluding Acquired In Process Cost | 13,337 | 10,991 | +21.3% |
Show Product Lines breakouts |
|||
| Early-stage · Reportable Segment | 4,881 | 3,917 | +24.6% |
| Late-stage · Reportable Segment | 8,456 | 7,074 | +19.5% |
| Selling, General & Administrative | 11,094 | 8,594 | +29.1% |
Show Business Segments breakouts |
|||
| Reportable Segment | 11,094 | 8,594 | +29.1% |
| Research And Development Asset Acquired Other Than Through Business Combination Written Off | 2,910 | 3,280 | -11.3% |
Show Business Segments breakouts |
|||
| Reportable Segment | 2,910 | 3,280 | -11.3% |
| Restructuring Settlement And Impairment Provisions | 484 | 861 | -43.8% |
| Non-Operating Income (Expense) | 571 | 219 | +160.7% |
| Cost Of Sales Operating Expenses And Other Net | 39,448 | 32,363 | +21.9% |
| Income Before Taxes | 25,731 | 12,680 | +102.9% |
| Income Tax Expense (Benefit) | 5,091 | 2,090 | +143.6% |
| Net Income | 20,640 | 10,590 | +94.9% |
Show Business Segments breakouts |
|||
| Reportable Segment | 20,640 | 10,590 | +94.9% |
| EPS (Basic) | 23 | 11.76 | +95.6% |
| EPS (Diluted) | 22.95 | 11.71 | +96.0% |
| Wtd Avg Shares (Basic) | 897.3 | 900.6 | -0.4% |
| Wtd Avg Shares (Diluted) | 899.3 | 904.1 | -0.5% |
| Interest Expense | 895 | 781 | +14.6% |
| Net Income (FY) | — | — | — |
Show Equity Components breakouts |
|||
| Retained Earnings | 20,640 | 10,590 | +94.9% |
| Comprehensive Income | 22,082 | 10,595 | +108.4% |
| Other Comprehensive Income | 1,442 | 5 | +28740.0% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 1,442 | 5 | +28740.0% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 7,268 | 3,268 | +122.4% |
| Accounts Receivable | 17,760 | 11,006 | +61.4% |
| Other Receivables Net Current | 2,395 | 2,270 | +5.5% |
| Inventory | 13,744 | 7,589 | +81.1% |
| Prepaid Expense Current | 14,315 | 8,341 | +71.6% |
| Other Assets Current | 147 | 266 | -44.7% |
| Total Current Assets | 55,629 | 32,740 | +69.9% |
| Non-Current Assets | |||
| Long Term Investments | 2,802 | 3,216 | -12.9% |
Show Fair Value By Measurement Basis breakouts |
|||
| Carrying Reported Amount Fair Value Disclosure | 2,802 | 3,216 | -12.9% |
| Goodwill | 5,898 | 5,770 | +2.2% |
| Intangible Assets Net Excluding Goodwill | 6,521 | 6,166 | +5.8% |
| Deferred Tax Assets | 9,959 | 8,001 | +24.5% |
| Property, Plant & Equipment | 24,675 | 17,102 | +44.3% |
| Other Non-Current Assets | 6,992 | 5,720 | +22.2% |
| Total Assets | 112,476 | 78,715 | +42.9% |
| Operating Lease Right-of-Use Assets | 1,260 | 1,050 | +20.0% |
| Intangible Assets (Q) | — | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Developed Technology Rights | 4,952 | 5,269 | -6.0% |
| Current Liabilities | |||
| Debt Current | 1,635 | 5,117 | -68.0% |
| Accounts Payable | 5,379 | 3,229 | +66.6% |
| Employee Related Liabilities Current | 2,375 | 2,094 | +13.4% |
| Sales Rebates And Discounts | 17,382 | 11,539 | +50.6% |
| Other Liabilities Current | 8,457 | 6,397 | +32.2% |
| Total Current Liabilities | 35,228 | 28,376 | +24.1% |
| Non-Current Liabilities | |||
| Long-Term Debt | 40,868 | 28,527 | +43.3% |
| Accrued Income Taxes Noncurrent | 5,875 | 4,061 | +44.7% |
| Other Non-Current Liabilities | 3,970 | 3,479 | +14.1% |
| Liabilities Noncurrent | 50,713 | 36,067 | +40.6% |
| Long-Term Debt (Q) | — | — | — |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level2 · Carrying Reported Amount Fair Value Disclosure | 42,503 | 29,307 | +45.0% |
| Fair Value Inputs Level2 · Estimate Of Fair Value Fair Value Disclosure | 39,799 | 26,249 | +51.6% |
Show Debt Instrument breakouts |
|||
| August 2024 Issuance Date Debt | 5,000 | — | — |
| August 2025 Issuance Date Debt | 6,750 | — | — |
| February 2023 Issuance Date Debt | 4,000 | — | — |
| February 2024 Issuance Date Debt | 6,500 | — | — |
| February 2025 Issuance Date Debt | 6,500 | — | — |
Show Long-Term Debt Type breakouts |
|||
| Floating-Rate Notes | 750 | — | — |
| Operating Lease Liabilities | 1,140 | 971 | +17.4% |
| Stockholders' Equity | |||
| Common Stock | 590 | 592 | -0.3% |
| Additional Paid In Capital Common Stock | 7,346 | 7,439 | -1.3% |
| Retained Earnings | 24,470 | 13,545 | +80.7% |
| Common Stock Shares Held In Employee Trust | -3,013 | -3,013 | 0.0% |
| Accumulated Other Comprehensive Income | -2,880 | -4,322 | +33.4% |
| Other Additional Capital | 22 | 31 | -29.0% |
| Total Stockholders' Equity | 26,535 | 14,272 | +85.9% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -1,987 | -2,179 | +8.8% |
| Accumulated Other Comprehensive Income | -2,880 | -4,322 | +33.4% |
| Accumulated Translation Adjustment | -1,149 | -2,390 | +51.9% |
| Additional Paid In Capital | 7,346 | 7,439 | -1.3% |
| Common Stock | 590 | 592 | -0.3% |
| Other | 255 | 246 | +3.7% |
| Retained Earnings | 24,470 | 13,545 | +80.7% |
| Trust For Benefit Of Employees | -3,013 | -3,013 | 0.0% |
| Total Liabilities & Equity | 112,476 | 78,715 | +42.9% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 1,997 | 1,767 | +13.0% |
| Increase Decrease In Deferred Income Taxes | -1,707 | -2,683 | +36.4% |
| Stock-Based Compensation | 626 | 646 | -3.1% |
| Gain Loss On Disposition Of Intangible Assets | -180 | -224 | +19.6% |
| Other Operating Activities Cash Flow Statement | 620 | 826 | -24.9% |
| Increase Decrease In Accounts And Other Receivables | -7,000 | -2,155 | -224.8% |
| Change in Inventory | -4,671 | -2,507 | -86.3% |
| Change in Prepaid & Other Assets | -6,609 | -3,331 | -98.4% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | 10,187 | 2,609 | +290.5% |
| Net Cash from Operations | 16,813 | 8,818 | +90.7% |
| Deferred Income Taxes | -1,707 | -2,683 | +36.4% |
| Investing Activities | |||
| Payments To Acquire Other Property Plant And Equipment | -7,841 | -5,058 | -55.0% |
| Proceeds From Sale And Maturity Of Other Investments | 964 | 374 | +157.8% |
| Payments To Acquire Other Investments | -645 | -677 | +4.7% |
| Proceeds From Sale Of Intangible Assets | 218 | 601 | -63.7% |
| Payments To Acquire In Process Research And Development | -3,008 | -3,346 | +10.1% |
| Other Payments To Acquire Businesses | -661 | -948 | +30.3% |
| Other Investing Activities | 1 | -248 | +100.4% |
| Net Cash from Investing | -10,972 | -9,302 | -18.0% |
| Financing Activities | |||
| Payments Of Dividends | -5,384 | -4,680 | -15.0% |
| Proceeds From Repayments Of Short Term Debt | -4,338 | -1,852 | -134.2% |
| Proceeds From Issuance Of Long Term Debt | 13,167 | 11,417 | +15.3% |
| Repayments Of Long Term Debt | -778 | -664 | -17.2% |
| Share Repurchases | -4,108 | -2,500 | -64.3% |
| Proceeds From Payments For Other Financing Activities | -772 | -491 | -57.2% |
| Net Cash from Financing | -2,213 | 1,230 | -279.9% |
| Supplemental | |||
| Income Taxes Paid | 10,814 | 6,562 | +64.8% |
| Interest Paid | 633 | 578 | +9.5% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 372 | -297 | +225.3% |
| Net Change in Cash | 4,000 | 449 | +790.9% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 7,268 | 3,268 | +122.4% |
Values in millions USD. Source: SEC EDGAR 10-K filing.